• Daré Bioscience received a Notice of Award from NIH’s NIAID for the second $1 million tranche of its DARE-HPV grant.
• Total NIAID SBIR funding for the persistent high-risk HPV program now stands at $2 million across the project period that began in late 2024.
• Funding supports non-clinical and translational work as Daré advances a Phase 2 trial, with topline data expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9726146) on May 26, 2026, and is solely responsible for the information contained therein.